Skip to Content

Mycapssa Approval Status

  • FDA approved: No
  • Brand name: Mycapssa
  • Generic name: octreotide
  • Company: Chiasma, Inc.
  • Treatment for: Acromegaly

Mycapssa (octreotide) is an oral formulation of the somatostatin analog octreotide (currently available as an injection) in development for the treatment of acromegaly.

On April 15, 2016, Chiasma, Inc. announced the receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the company’s New Drug Application for Mycapssa (octreotide) capsules for the maintenance treatment of adult patients with acromegaly. The FDA issues CRLs to indicate that the review cycle for an application is complete and that the application is not ready for approval in its present form.

Development Status and FDA Approval Process for Mycapssa

Apr 15, 2016FDA Issues Complete Response Letter for Mycapssa New Drug Application
Aug 17, 2015Chiasma Announces FDA Acceptance For Filing of New Drug Application for Octreotide Capsules in Acromegaly
Jun 15, 2015Chiasma Submits New Drug Application to U.S. FDA for Octreotide Capsules in Acromegaly

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.